Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

39.61USD
25 Apr 2019
Change (% chg)

$0.24 (+0.61%)
Prev Close
$39.37
Open
$39.25
Day's High
$39.83
Day's Low
$39.17
Volume
17,201,238
Avg. Vol
25,285,970
52-wk High
$46.47
52-wk Low
$34.37

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.69
Market Cap(Mil.): $218,574.50
Shares Outstanding(Mil.): 5,551.81
Dividend: 0.36
Yield (%): 3.66

Financials

  PFE Industry Sector
P/E (TTM): 22.91 62.05 62.41
EPS (TTM): 1.72 -- --
ROI: 7.74 12.20 11.81
ROE: 15.37 13.14 12.64

Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

Apr 22 2019

UPDATE 1-Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

April 22 The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

Apr 22 2019

Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

April 22 The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

Apr 22 2019

Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.

Apr 18 2019

Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

April 18 A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.

Apr 18 2019

U.S., China key to GSK's consumer venture with Pfizer

LONDON The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the companies look to build on strong existing positions in those markets.

Apr 04 2019

U.S., China key to GSK's consumer venture with Pfizer

LONDON, April 4 The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the companies look to build on strong existing positions in those markets.

Apr 04 2019

Shareholder pushing for mandatory arbitration seeks to block J&J's annual meeting

There has been a significant escalation in the fight over whether corporations can require shareholders to arbitrate claims against the company.

Mar 27 2019

Bristol-Myers, Pfizer defeat Eliquis bleeding risk lawsuits on appeal

A federal appeals court on Tuesday upheld the dismissal of 60 lawsuits alleging Bristol-Myers Squibb and Pfizer Inc concealed information about the dangers of using their blood thinner Eliquis, dealing a major blow to the multidistrict litigation over the drug.

Mar 26 2019

Pfizer buys stake in French gene therapy firm Vivet

Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

Mar 20 2019

Earnings vs. Estimates